Literature DB >> 1287674

Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B.

E Hamel1.   

Abstract

This paper summarizes published data on the interactions of tubulin with antimitotic compounds that inhibit the binding of vinca alkaloids to the protein. These are all relatively complex natural products isolated from higher plants, fungi and marine invertebrate animals. These agents are maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B and their congeners. Effects on tubulin polymerization, ligand binding interactions and structure-activity relationships are emphasized.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1287674     DOI: 10.1016/0163-7258(92)90028-x

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  33 in total

Review 1.  Potential of plant-derived natural products in the treatment of leukemia and lymphoma.

Authors:  David M Lucas; Patrick C Still; Lynette Bueno Pérez; Michael R Grever; A Douglas Kinghorn
Journal:  Curr Drug Targets       Date:  2010-07       Impact factor: 3.465

Review 2.  Targeted approaches for the management of metastatic prostate cancer.

Authors:  Kathleen W Beekman; Maha Hussain
Journal:  Curr Oncol Rep       Date:  2006-05       Impact factor: 5.075

Review 3.  Eribulin -- a review of preclinical and clinical studies.

Authors:  Umang Swami; Imran Chaudhary; Mohammad H Ghalib; Sanjay Goel
Journal:  Crit Rev Oncol Hematol       Date:  2011-04-14       Impact factor: 6.312

4.  Structural insight into the inhibition of tubulin by vinca domain peptide ligands.

Authors:  Anthony Cormier; Matthieu Marchand; Raimond B G Ravelli; Marcel Knossow; Benoît Gigant
Journal:  EMBO Rep       Date:  2008-09-12       Impact factor: 8.807

Review 5.  Current status and contemporary approaches to the discovery of antitumor agents from higher plants.

Authors:  Garima Agarwal; Peter J Blanco Carcache; Ermias Mekuria Addo; A Douglas Kinghorn
Journal:  Biotechnol Adv       Date:  2019-01-08       Impact factor: 14.227

6.  A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs.

Authors:  Andrea E Prota; Katja Bargsten; J Fernando Diaz; May Marsh; Carmen Cuevas; Marc Liniger; Christian Neuhaus; Jose M Andreu; Karl-Heinz Altmann; Michel O Steinmetz
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-11       Impact factor: 11.205

7.  Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera.

Authors:  M A Robin; M Maratrat; M Le Roy; F P Le Breton; E Bonierbale; P Dansette; F Ballet; D Mansuy; D Pessayre
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

8.  Operationally simple and efficient workup procedure for TBAF-mediated desilylation: application to halichondrin synthesis.

Authors:  Yosuke Kaburagi; Yoshito Kishi
Journal:  Org Lett       Date:  2007-02-15       Impact factor: 6.005

Review 9.  Potential clinical applications of halichondrins in breast cancer and other neoplasms.

Authors:  Vanesa Ortega; Javier Cortés
Journal:  Breast Cancer (Dove Med Press)       Date:  2012-02-08

10.  Ammosamides A and B target myosin.

Authors:  Chambers C Hughes; John B MacMillan; Susana P Gaudêncio; William Fenical; James J La Clair
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.